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Genome-wide association studies are rapidly unraveling
genetic susceptibility variants that are implicated in the
etiology of common multifactorial diseases such as coro-
nary heart disease, type 2 diabetes, non-familial forms of
breast cancer and age-related macular degeneration [1].
Expectations about the future impact of these discoveries
on preventive and clinical health care practice are high [2,
3]. Future use of genetic tests is foreseen for the prediction
of disease susceptibility, targeting pharmacotherapy and
tailoring lifestyle and health behavior recommendations.
Fueled by the enormous progress in gene discovery, many
researchers are already investigating the prediction of
common diseases based on genetic profiling, the simulta-
neous testing of multiple susceptibility variants [4], and an
increasing number of companies already offer personalized
lifestyle health recommendations and nutritional supple-
ments based on clients’ genetic profiles [5]. Despite the
current euphoria, the predictive value of genetic profiling is
still limited for most disorders, with only some promising
exceptions. [4, 6–9] The major limitation to date is that
only a fraction of the genetic factors involved have been
identified, for most disorders less than 20 [1], explaining
not more than a few percentages of the heritability.
While we may expect that a large number of genetic
variants will be discovered in the next few years, estab-
lishing a solid evidence base for genomics applications in
clinical and public health care may take longer given the
number of steps to be taken. Khoury and colleagues have
described a framework for the continuum of translation
research that is required to move genomics research find-
ings to clinical and public health applications that benefit
population health [10]. The four phases of translation
researches include (1) translation of basic genomics
research into a potential health care application; (2) eval-
uation of the application for the development of evidence-
based guidelines; (3) evaluation of the implementation and
use of the application in health care practice; and (4)
evaluation of the achieved population health impact [10].
Translation research in genomics starts after gene dis-
covery [10]. In common diseases, where numerous genetic
factors may be implicated, genes are discovered by dem-
onstrating robust genetic association, not in a single study
but in meta-analyses or pooled analyses of large-scale
studies [11–13]. A major challenge in common diseases is
to decide when we have discovered sufficient genetic
variants to begin translation research. One may argue that
now the time is right because the studies so far likely have
identified the common variants with the strongest effects
and that further studies will only add weak susceptibility
variants. For instance the complement factor H gene was
the first common gene discovered to be involved in age-
related macular degeneration (AMD) using not more than
100 patients and 50 controls [14]. Typical gene discovery
studies include 1,000s of patients and are able to detect
variants with odds ratios as low as 1.05–1.10. Yet, also a
very large number of weak susceptibility variants may
further improve risk prediction [15]. Furthermore, stronger
genetic effects may still be found for gene-gene and gene–
environment interactions. Many groups of researchers are
currently pooling their data in large consortia, which
together will have sufficient power to model and detect
interactions. Another avenue to pursue is to target more
rare variants with strong genetic effects in specific popu-
lations. Genetic associations may not only differ between
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ethnic groups, but also within. In Europe, there may be
differences in genetic and other risk factors between
northern and southern countries (e.g., multiple sclerosis,
breast and other cancers, lipids), which asks for gene-dis-
ease association studies in specific populations, e.g., [16,
17] also because true genetic heterogeneity between pop-
ulations may later impact the global applicability of
predictive genetic tests. Because gene–gene and gene–
environment interactions have not been extensively studied
to date, further major advances in unraveling the genetic
basis of common diseases may certainly be expected.
All recent studies that investigated the combined pre-
dictive value of multiple genetic variants were phase 1
studies. In most studies, the per allele effects of the risk
genotypes typically ranged from 1.1 tot 1.4, except for
AMD and hypertriglyceridemia [4, 6, 8]. From an epide-
miological perspective, investigating the predictive value
of a limited number of susceptibility genes with weak
effects seems somewhat overoptimistic as a priori high
predictive value is not expected [18]. The predictive value
of genetic profiling, often investigated in terms of the
discriminative accuracy indicated by the area under the
receiver operating characteristic curve (AUC), is deter-
mined by the number of variants, the frequency of the risk
genotypes and their strength of association to disease risk
[15]. To reach appreciable predictive value for genetic
profiling, we either should be able to include up to tens or
hundreds of weak susceptibility genes or a few variants
with strong effects as in AMD and hypertriglyceridemia
[15]. These variants can be single gene effects, but can also
be derived from gene–gene or gene–environment interac-
tions. In the absence of stronger genetic risk factors, phase
1 studies on the predictive value of genetic profiling will
continue to yield disappointing results.
Phase 2 research specifies that genetic profiling is
evaluated in the population of its intended use. Assessment
and replication of the predictive value in independent
populations is always important, but particularly when the
combined association of multiple variants is initially
demonstrated in a case–control study. Most genetic asso-
ciation studies are conducted in case–control studies, and
often these include highly selected cases (familial, early
onset) and controls (persons with no pathology late in life)
to maximize the statistical power. Such studies are more
likely to overestimate the combined effect of multiple
genes, and extrapolation of estimates from such well-
defined study populations to a general population may not
be possible [19]. For example, Maller et al. reported that
individuals who had risk variants on five variants had 285-
fold higher risk of age-related macular degeneration
(AMD) then individuals who had none [6]. Yet, they
compared two extreme groups, namely those with end-
stage AMD and those with no or fewer than 10 small
drusen without pigment abnormalities and they did not
include patients with early features of AMD [7]. Although
this design is powerful and valid for gene discovery, the
findings are not informative for the evaluation of genetic
testing. Genetic testing for AMD should be evaluated in a
prospective cohort study, either a general population cohort
of elderly if the intended use is to predict end-stage A´MD
in asymptomatic individuals, or a sub-cohort of patients
with early AMD if the intended use is to predict worse
prognosis [7]. In contrast to what is common in gene dis-
covery research, evaluations of the predictive value in
population-based cohorts do not necessarily need extre-
mely large datasets, as minimal predictive value or
minimal improvements in predictive value are generally
not of interest from a clinical or public health perspective.
Numerous epidemiological cohorts are available and are
sufficiently large for this purpose. Examples of population-
based cohort studies include the Framingham heart study,
European Prospective Investigation into Cancer and
Nutrition, the Rotterdam study and LifeLines among
adults, and the Avon Longitudinal Study of Parents and
Children, Generation R study, and Norwegian Mother and
Child Cohort study among mothers and newborns [20–27].
Most of these studies already include extensive genotype
data using high throughput genotyping arrays.
Evaluating genetic profiling in the population of its
intended use requires that the intended use is already
known. The question who will be tested and for what
purpose is essential in the evaluation of the usefulness of
genetic profiling [28], and becomes particularly relevant in
phase 2 research. Genetic profiling may be used for tar-
geting preventive or therapeutic interventions to subgroups,
either to individuals who have the highest risk of disease or
the worst prognosis or to individuals who benefit most from
the intervention. Depending on this intended use, genetic
profiling should predict risk of disease/prognosis or treat-
ment response. Phase 2 research can investigate whether
effective preventive or therapeutic strategies that are tar-
geted on the basis of traditional risk factors are more
effectively and efficiently allocated when risk prediction
would be based on genetic factors. Examples include
intensive cancer surveillance programs for individuals
from high-risk families and breast cancer screening to
women over 50 years of age [29]. Phase 2 research is of
less interest when the interventions are an obvious benefit
for the total population because they target multiple dis-
orders, e.g., smoking cessation and weight reduction, or
when no intervention is available. Even when genetic
profiling shows high predictive value in phase 2 research,
in the absence of effective interventions it will not pass
phase 3 and 4.
Notwithstanding the growing availability of commer-
cial genetic testing via the internet, evidence-based
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applications of genetic profiling in clinical and public
health care practice are still a far future prospect. The
recent empirical and modeling studies on the predictive
value of genetic profiling have taught us that the identi-
fication of stronger genetic associations is paramount for
higher predictive value. Most of the scientific attention
should, therefore, remain focused on basic genetic epi-
demiological research, unraveling the genetic basis of
common diseases in all its complexity and all its inter-
actions. The progress in genomic research will
undoubtedly increase our understanding of disease etiol-
ogy, leading to the identification of new biomarkers and
risk factors that can be used in risk prediction as well as
to the development of novel preventive and therapeutic
interventions. At this time, phase 1 translation research
can contribute by investigating on an aggregate level the
conditions to be met for the successful implementation of
genetic profiling in public health and clinical practice. For
example, to identify the promising applications we need
to know when we have sufficient understanding of the
contribution of genetic factors to start phase 1 research,
and what level of predictive value is considered useful to
warrant phase 2 research, e.g., compared to risk prediction
based on traditional risk factors, among other questions.
The results of such studies can be used to prioritize the
translation research agenda so that research time and
money are allocated to the most promising of all expected
applications.
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